Leadership Team

Giovanni Caforio, MD, has been chief executive officer of Bristol Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. In May 2017, he assumed the role of chairman of the board.

As CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, Bristol Myers Squibb is evolving its operating model, in order to increase speed and competitiveness. 

With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture — one driven by innovation, speed, accountability and passion. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion. 

Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by his work as the company’s chief commercial officer. 

Giovanni joined Bristol Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. to assume the role of senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. organization in 2011. Prior to joining Bristol Myers Squibb, Giovanni spent 12 years with Abbott Laboratories in a number of leadership positions. 

Born and educated in Italy, Giovanni received his MD from the University of Rome. 

Updated: May 2017

Christopher Boerner is chief commercialization officer of Bristol Myers Squibb, where he leads commercial strategy and execution across all geographies. He also currently serves as the executive sponsor of the Bristol Myers Squibb Network of Women (B-NOW) People and Business Resource Group. In his previous role, Chris was head of international markets at Bristol Myers Squibb, accountable for commercial activities in all ex-U.S. markets. He joined the company in February 2015. 

“I look forward to continuing to help BMS deliver on our mission of bringing transformational medicines to patients,” Chris said. “By focusing on innovation and execution, we can strengthen our ability to bring innovative medicines to patients faster.”

Prior to joining Bristol Myers Squibb, Chris served as the executive vice president of commercial for Seattle Genetics, Inc., where he led all commercial activities for the company, as well as senior vice president of commercial and vice president of marketing.

Before joining Seattle Genetics, Chris worked for Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked for Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin^®. Prior to Genentech, he worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.

Chris received his PhD and MA in business administration from the Haas School of Business at the University of California, Berkeley, and holds an AB in economics and history from Washington University in St. Louis.

Updated: November 2021

David Elkins is the executive vice president and chief financial officer responsible for Global Business Operations, which includes Business Insights and Analytics, Global Finance and Global Procurement. David also currently serves as the executive sponsor of the company’s PRIDE Alliance People and Business Resource Group. 

“Our team creates incredible partnerships across the business to secure and build value for the company and our patients. Our team also plays a vital part in promoting health — our financial health,” says David. “It is our role to ensure we strategically and efficiently invest and deploy our resources in a manner that maximizes value for our patients and all our other stakeholders as we advance the need for innovative medicines.”

David joined Celgene in July 2018 after several years at Johnson & Johnson (J&J), where he served as chief financial officer for that company’s Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, his experiences include EVP & chief financial officer of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca, and he began his career in finance at the Boeing Company in 1991. 

David earned his bachelor’s degree from the University of Delaware, an MS from the University of Pennsylvania, and an MBA from Drexel University.

Updated: November 2021

As vice president and chief diversity and inclusion officer, Pamela Fisher drives our global diversity and inclusion (GD&I) business strategy and operating plans, connects our GD&I commitments to business performance, innovation and patient outcomes, and continues to strengthen and shape our diverse and inclusive culture. She provides leadership to our Global Diversity Inclusion Council and People and Business Resource Groups.

In addition to serving as a member of the leadership team, Pam reports to our chief human resources officer, Ann Powell.

“At BMS, we understand the value and impact of having a workforce that reflects the patients and communities we serve, and a culture of inclusion and belonging where everyone’s unique perspective collectively drives greater innovation and healthcare solutions,” Pamela says. “ We remain committed to advancing our D&I strategy, addressing the evolving needs of patients and driving more equitable and sustainable health outcomes around the world.”

Pam joins the company with more than 20 years of global corporate experience in diversity and inclusion management, philanthropy, communications and government relations. In her most recent position at Johnson & Johnson, from 2017 until joining Bristol Myers Squibb, she served as head of diversity, equity & inclusion global strategy partnerships and was on the leadership team that launched an evidence-based D&I strategy that reached diverse and multicultural patients and consumers, and increased workforce diversity and sentiment on inclusion. Prior to that, she was with Quest Diagnostics from 2015 to 2017 and served as president of The Quest Foundation and executive director of global inclusion and corporate social impact. She also led News Corp's diversity and inclusion strategy and has held leadership positions at News Corp and 20^th Century Fox Entertainment.

Pam earned her undergraduate degree in communications from George Mason University.

Updated: November 2021

Cari Gallman, chief compliance and ethics officer, is responsible for reinforcing the company’s strong culture of ethics and integrity; she champions efforts that ensure our operations are conducted in compliance with ethical business practices, our Principles of Integrity, and laws and regulations in the global markets in which we operate. In addition to reporting to the General Counsel and CEO, Cari also reports to the Chair of the Audit Committee of the Board of Directors.

“Our deep and unwavering commitment to ethics and integrity provides the foundation for everything we do. It guides how we interact with our colleagues and external partners, as well as the work we do on behalf of our patients and communities around the world,” she says.

Cari has 15 years of combined experience in pharmaceutical law and compliance. She began her legal career in private practice representing pharmaceutical and medical device manufacturers in government enforcement and regulatory matters. In her practice, she regularly advised companies on how to design and implement robust compliance policies to meet business objectives as well as legal needs. She joined the company in 2015 and assumed positions of increasing responsibility, including as head of the legal team supporting the Global Oncology Commercialization and Development organizations. 

She earned a bachelor’s degree in political theory from Princeton University and a JD from Harvard Law School.

Updated: November 2021

As chief medical officer, Global Drug Development, Dr. Samit Hirawat oversees late-stage product development across all therapeutic areas. In this role, Samit and his organization focus on enabling the rapid progression and delivery of late-stage assets, from proof-of-concept to commercialization, through world-class clinical trial design and operations. He also currently serves as the executive sponsor of the Cultivating Leadership for Millennials and Beyond (CLIMB) People and Business Resource Group. 

Samit joined Bristol Myers Squibb in 2019 with extensive drug development experience, most recently serving as Executive Vice President and Head of Oncology Development for Novartis. Previously, he led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.

Samit earned his bachelor of medicine, bachelor of surgery (MBBS) at Sawai Man Singh Medical College in India, and completed his internal medicine residency and medical oncology training at North Shore University Hospital, New York.

Updated: November 2021

As executive vice president, general counsel, Sandy Leung serves as legal advisor to the Board of Directors and company executives, and is responsible for shaping the company’s legal strategy. Sandy is also responsible for Environment, Health & Safety & Sustainability, Corporate Security and Philanthropy. In addition, she currently serves as the executive sponsor of the Black Organization for Leadership and Development (BOLD) People and Business Resource Group.

“The accelerating pace of science, governmental policies and regulations and overall global complexity across our industry requires us to be even more agile than ever,” says Sandy. “Our legal team brings strategic value across all aspects of our business through practical and sound counsel that guide our company in its mission to help patients.”

Sandy joined Bristol Myers Squibb in 1992 as a staff attorney in the litigation department. In 1996, she became assistant counsel and one year later was named associate counsel. In 1999, Sandy was appointed to the position of counsel and corporate secretary. In 2006, she was appointed acting general counsel and in 2007 was named general counsel. In 2014, Sandy was named executive vice president.

Prior to joining the company, Sandy was a prosecutor in the Manhattan District Attorney’s Office.

“My advice to those aspiring to management positions is to be good at what you do. You have to be willing to do the hard work and bring excellent judgment and expertise to the table. Most important, you must have great personal integrity and be someone people can trust. If people trust you, they will feel comfortable seeking your advice. Also, be respectful of people, not just your superiors but everyone.”

Sandy earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.

Updated: November 2021

Greg Meyers leads the Information Technology organization, positioning the company for success in the rapidly evolving digital age. His priority is to accelerate the company’s strategy through digital technology and data enablement, adopting new approaches to digital health, and fostering long-term partnerships with external technology companies and digital innovators. He is also responsible for ensuring we have both secure and reliable IT infrastructure and the platforms necessary to drive our ambitious innovation agenda.

“Digital innovation, computer and data science are the disciplines that will create breakthroughs in our understanding of biology and transform the way the life sciences industry operates at a fundamental level,” Greg said. “The state of artificial intelligence and machine learning in life sciences is similar to where we were with personal computers in the 1980s - we are just getting started and there is so much ahead to discover! Technology and digital capabilities will also catalyze our ways of working - from how we develop medicines, to how we improve patient experience to how we run our core business operations. We are excited and ready to harness all of the possibilities that lie ahead.”

Greg is an accomplished senior executive with extensive experience as an agent of change and during his career, he has held profit & loss roles, led digital transformations, managed complex cybersecurity threats in diverse geopolitical environments, and is recognized as a thought leader and futurist in several industries.

Greg holds a bachelor’s degree in marketing from Rutgers University with a minor in computer science, and a master’s degree in business administration from Temple University.

Updated: January 2022

Elizabeth Mily is executive vice president, Strategy & Business Development, at Bristol Myers Squibb. In this role, she oversees the company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives. Elizabeth is instrumental in our approach to source scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. Elizabeth was appointed to the position in March 2020.

“I'm excited to join Bristol Myers Squibb at a time when the company is poised for tremendous growth through its high-performing brands, upcoming new product launches and robust pipeline.” Elizabeth says. “I look forward to playing an important role in enhancing our capability to pursue the next generation of medicines.”

Prior to joining Bristol Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences business, including the BioPharma, Life Science Tools and Diagnostics sectors. Prior to joining Barclays, Elizabeth served as head of Corporate Strategy and Development at Thermo Fisher Scientific. Previously, she was a managing director and senior coverage officer within the Healthcare Department of the Investment Banking Division at Goldman, Sachs & Co.

Elizabeth holds a master of science in foreign service from Georgetown University and a bachelor of arts in German literature and European history from The Ohio State University. She was also a Fulbright Scholar to the Universities of Cologne and Hamburg, Germany. Elizabeth also completed a Congress-Bundestag scholarship in Bonn, Germany.

Elizabeth is an active alumnus of The Ohio State University, sitting on the Dean’s Advisory Council of the Fisher College of Business. She also serves as a trustee of the Stephen Gaynor School.  

Updated : March 2020

Ann M. Powell is the global head of Human Resources with direct responsibility for driving the corporation’s global capabilities in talent management, culture and organizational effectiveness tied directly to Business performance. She also currently serves as the executive sponsor of the Disability Advancement Workplace Network (DAWN) People and Business Resource Group. 

Ann works across the enterprise to support Bristol Myers Squibb's commitment to creating an energizing work experience and a culture that is powerfully diverse and broadly inclusive, where individuals are encouraged to exceed their potential and inspired to make innovative contributions for our patients and the global communities in which they live and work.

“The courage and passion of our workforce is truly inspiring and drives an even higher level of engagement in making a difference in the lives of patients,” says Ann.

Ann’s industry experience and expertise lie in executive compensation, leadership development, change management, diversity/inclusion, training design and delivery, talent acquisition, labor relations, mergers and acquisitions, divestitures and start-ups.

With a career spanning both international and domestic assignments, Ann has held leadership roles of increasing responsibility within both the chemical and pharmaceutical industries, including Dow Chemical and Wyeth Pharmaceuticals. Prior to joining Bristol Myers Squibb in 2013, Ann was the chief human resources officer for Shire Pharmaceuticals.

Ann earned a bachelor’s degree from Iowa State University and a master’s degree in industrial relations from the University of Minnesota.

Updated: November 2021

Karin Shanahan oversees worldwide product development, manufacturing and supply for Bristol Myers Squibb as executive vice president, Global Product Development & Supply (GPS). GPS develops and produces active ingredients and drug products and delivers the company’s medicines throughout the world. The GPS team achieves this mission through a relentless focus on innovation, quality, safety and agility.

“I’m excited to return to Bristol Myers Squibb, where I began my career in the pharmaceutical industry. Though I’ve worn many hats in the industry since then, I was drawn back to Bristol Myers Squibb because of its unwavering dedication to quality and delivering innovative medicines to patients in need,” says Karin. “I am honored to help lead the integral GPS team as we navigate an everchanging landscape.”

Karin began her career in the pharmaceutical industry at Bristol Myers Squibb in corporate procurement, global supply chain, and global quality. Karin moved into manufacturing operations, leading two manufacturing sites in Billerica, MA, and Latina, Italy. After almost 14 years with Bristol Myers Squibb, Karin joined Becton-Dickenson as a leader of global operations,  followed by Catalent Pharmaceuticals where she led global Biologics operations. In 2013, Karin joined Teva Pharmaceuticals as senior vice president and chief operating officer of global operations, where she led global Manufacturing Science & Technology (MS&T) and Network Strategy and a network of 25 sites across Europe and the Americas. Most recently, Karin served as senior vice president of Global Biologics & Sterile Operations at Merck.

Karin earned a bachelor’s degree in political science and international relations from Rutgers University and a master’s degree in jurisprudence (MSJ), pharmaceutical and device law, from Seton Hall Law School. 

Updated: May 2022

As chief of staff, Catalina Vargas supports the office of the chief executive officer and plays a strategic role in driving enterprise initiatives. 

Catalina has more than 20 years of experience in the biopharma industry and has held positions of increasing responsibility in a range of local, regional and global roles in global strategic sourcing and procurement as well as manufacturing; she has also served as a product portfolio leader. 

She joined Bristol Myers Squibb in 2018 as vice president, Strategic Sourcing and Procurement, Global Product Development and Supply, managing a complex supply chain need to ensure the uninterrupted supply of medicines to our patients. Prior to joining Bristol Myers Squibb, she was with Pfizer for 18 years in a number of leadership positons. 

“I was drawn to the biopharma industry to help bring much-needed treatments to patients with serious diseases,” she says. “In my roles in procurement, a strategic area that helps advance a company’s competitive capabilities, I was proud to play a part in delivering innovative medicines to patients.”

Born and educated in Colombia, Catalina earned her bachelor’s degree in industrial engineering from Universidad Javeriana and a graduate degree in finance and capital markets from Universidad de La Sabana.

Updated: March 2021

Rupert Vessey leads Research and Early Development, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also works closely with Business Development to identify external sources of innovation. In addition, he currently serves as the executive sponsor of the Organization for Latino Achievement (OLA) People and Business Resource Group and the Bristol Myers Squibb STEM Council. 

“My colleagues and I believe in the power of scientific innovation to change the course of human health,” says Rupert. “That kind of culture and dedication is my most powerful motivator when I come to work each day.”

Rupert joined Bristol Myers Squibb from Celgene, where he served as president of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent ten years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases. 

Rupert graduated from Oxford University in the United Kingdom with degrees in physiological sciences (MA), clinical medicine (BM, BCh) and a doctor of philosophy (DPhil) in molecular immunology. He is an elected fellow of the Royal College of Physicians.

Updated: November 2021

As senior vice president, Global Medical Affairs, Estelle Vester-Blokland leads the company’s efforts to implement the safe and appropriate use of its medicines into clinical practice and gather insight into medical practices and patient needs from stakeholders. Global Medical Affairs collaborates with clinical drug development and the commercial organization to gain a deep understanding of medical needs and help deliver innovative medicines to patients.

As a member of the Bristol Myers Squibb leadership team, Estelle reports to our chief commercialization officer, Chris Boerner.

“Global Medical Affairs plays a critical role in engaging the medical community and implementing our science into clinical practice,” Estelle says. "With our innovative portfolio of therapies, and one of the most diverse and promising pipelines in the industry, we must clearly demonstrate the value of our medicines for patients and healthcare systems to help inform clinical decisions in a dynamic healthcare environment.”

Estelle’s valuable industry leadership and insight comes from more than 25 years of experience in medical affairs and product strategy across the U.S. and Europe. Before rejoining Bristol Myers Squibb in 2021, she spent two years at Novartis as worldwide head of Medical Affairs for Neuroscience; she has also served as a lifecycle leader in Global Product Strategy and head of Personalized Medicine in Global Medical Affairs at Roche. A physician by training, her background spans several therapeutic areas, including neuroscience and oncology; she is passionate about individualized, patient-centered care.

Estelle earned her doctor of medicine degree at Utrecht University in the Netherlands and worked for two years as an internal medicine physician before joining the industry.

Updated: December 2021

As executive vice president, Corporate Affairs, Michelle Weese oversees the company’s initiatives to protect, promote and enhance the Bristol Myers Squibb brand and reputation through strategic communications, government relations and policy, corporate social responsibility and patient advocacy. She also currently serves as the executive sponsor of the Pan Asian Network (PAN) People and Business Resource Group. 

Michelle joins Bristol Myers Squibb from the global food and beverage company Danone, where she served for two years as general secretary for North America and also led strategic corporate functions, including government and public affairs, communications, community affairs, scientific affairs and sustainable development for North America.

In 2009 she founded the private consulting firm, strat-igence, serving as its CEO and working with a range of clients from the biopharmaceutical and consumer packaged goods industries, including Johnson & Johnson, Church & Dwight, PepsiCo and Unilever, on issues such as crisis management, corporate affairs and corporate transformation. Prior to that, she held positions of increasing leadership responsibility in corporate affairs at Mars, Inc. including serving as global head of Communications. 

“Our role as biopharma leader has never been more important,” says Michelle. “In an evolving global market, this is a critical time to ensure that the innovative and transformative work being done by the company across multiple fronts is being communicated to our patients, policymakers, colleagues and broader stakeholders.”

Michelle earned her bachelor’s degree in journalism from Georgia State University. 

Updated: November 2021